# ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Canonical URL: https://biopharmsignal.com/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgar-e952538a
Ticker: ALXO
Company: ALX Oncology
Source: ALX Oncology
Published: 2026-06-30 12:00 EST
Original Source URL: https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-appoints-scott-garland-chairman-board-and-michael
## Summary

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc.

## Article Body
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc.
## Recent Company News
- 2026-06-30 20:40 EST — [ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-b37a2f05) — Source: ALX Oncology
- 2026-06-30 12:00 EST — [ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel](https://biopharmsignal.com/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgar-e952538a) — Source: ALX Oncology
- 2026-06-25 13:46 EST — [ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: ALX Oncology
- 2026-06-25 13:46 EST — [ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: ALX Oncology
- 2026-06-25 13:46 EST — [ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression](https://biopharmsignal.com/news/ALXO/alx-oncology-s-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression) — Source: ALX Oncology
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)